5 public procurers from 4 countries will procure innovative ICT-enabled monitoring solutions to improve health status and optimise hypertension care. HSMonitor will make person-centred care reality - giving the patient the steering wheel - for optimal health outcomes. The procurers have set a comprehensive framework for requirements and solution design consisting of 9 building blocks in three domains, to be addressed in an integrated ICT-enabled hypertension care solution. HSmonitor will apply the internationally acclaimed Chronic Care Model to specify support needs for hypertensive patients at all stages. Self-management and treatment will be supported by personalised guidelines and making the best use of clinical data. In this way a quality culture in healthcare will be fostered and learning healthcare systems made reality. Suppliers will be rigorously evaluated after each of the procurement phases, comprising (I) an open market consultation, (II) specification of architecture and system aligned to requirements of patients, peers and providers, (III) prototype development and testing with end-users and (IV) effectiveness proven in a trial with 500 patients and 150 professionals. Fully rolled out in the procurer countries, enabled by procurers with the authority and capacity in their countries and regions, HSMonitor will serve 31 million patients with hypertension. Reductions in hypertension-related complications promise cost relief of € 5 billion over 7 years in the five procurer countries. Suppliers can expect a turnover of € 1 billion a year. Proven ability to cover the four different health systems promises HSMonitor suppliers easy entry into other EU markets and beyond, a very strong contribution to overcoming fragmentation of demand and fostering the global market.

WE4AHA will advance the effective, large-scale uptake and impact of Digital Innovation for Active and Healthy Ageing (AHA), building on a comprehensive set of support and promotion services. Through WE4AHA’s centralised administration, coordination and external communication, the relevant stakeholders will be mobilised to help develop and implement three EU guided activities: Innovation to Market (I2M), Blueprint Digital Transformation of Health and Care for the Ageing Society, and EIP on AHA. WE4AHA will support the definition and execution of an I2M plan, further development of the Blueprint to drive the policy vision on digital innovation, and the consolidation of EIP on AHA Action Groups and Reference Sites. It will connect demand- and supply-side stakeholders through matchmaking, twinning, assessing innovative interventions using MAFEIP, and fostering engagement and many other support activities. It will leverage additional private and public investments by mobilising a growing number of stakeholders in Europe’s digital health and care and silver economy sectors - industry, public authorities, end users, financial institutions, investors, insurers, and research communities committed to innovate on a large-scale. WE4AHA will draw on its numerous, strong synergies and links to relevant H2020 R&I actions and other EU and international programmes. The highly interdisciplinary consortium will ensure the proper execution of the work plan by leveraging the partners’ access to expertise and evidence. The consortium composition is an unparalleled matching of partners with strategic competences in health and active ageing and leading experts in policy analysis, research and innovation oriented to business, ICT enabling technologies, stakeholder engagement, communication, dissemination and the multiplier effect. Additional support is provided through a pool of experts and an Advisory Board of key stakeholder organisations with high-level competences in relevant fields.

Public procurers in ProEmpower aim to procure a disease self-management solution to help meet the imminent threat of a diabetes epidemic. ProEmpower will make person-centred care reality - giving the patient the steering wheel - for optimal health outcomes. Very significant synergies will be reaped by supporting all 10 action areas of diabetes management in an integrated ICT solution. Early detection, personal decision support, self management and peer support are to be delivered from a platform with full interoperable and secure access to the necessary devices and health records. ProEmpower will apply the internationally acclaimed Chronic Care Model to specify support needs for type 2 diabetes at all stages. Self-management and treatment will be supported by personalised guidelines and making the best use of clinical data. In this way a quality culture in healthcare will be fostered and learning healthcare systems made reality. Suppliers will be rigorously evaluated after each of the four procurement phases, comprising (I) an open market consultation supported by the European eHealth Competition, (II) specification of architecture and system aligned to requirements of patients, peers and providers, (III) prototype development and testing with end-users and (IV) effectiveness proven in a trial with 200 patients and 40 professionals. Fully rolled out in the four countries, enabled by procurers with the authority and capacity in their countries and regions, ProEmpower will serve 12 million diabetes patients. Reductions in diabetes-related death, amputation, blindness and renal failure promise cost relief of € 53 billion over 7 years in the four countries. Suppliers can expect a turnover of € 5 billion a year. Proven ability to cover the four different health systems promises ProEmpower suppliers easy entry into other EU markets and beyond, a very strong contribution to overcoming fragmentation of demand and fostering the global market.

This innovation action will give a powerful impulse to implementation of ISO IDMP (ID of Medicinal Products) standards in EU Member States drug databases, supporting safe cross-border ePrescription/eDispensation and effective pharmacovigilance. Once EU-interoperable data on medicines taken by patients become available, further benefits will accrue through better health data for improved clinical decision support, patient empowerment, public health and clinical research. New opportunities will arise for pharma industry, software developers, SMEs providing smart apps and others, thereby fostering their innovation capacity and competitiveness. The many challenges still to be faced on this road will be tackled by a powerful consortium assembling all relevant actors, with critical mass for impact throughout the EU. After 10 years of development, the IDMP suite of standards is ready for implementation. Though some isolated implementation work has started, the time is now ripe for a more concerted effort towards large-scale implementation, contributing to this global interoperability endeavour and delivering benefits to EU citizens. Project ambition centres on conversion of key regulatory and clinical processes to use IDMP. These information value chains must be converted over their full length from data input to data repositories to data usage. Project work spans all three areas, focussing on the most challenging, the implementation of EU and national SPOR (substances, products, organisations, referentials) data bases, including establishing an EU Substance Reference System (EU-SRS). Such information is fundamental to cross-border ePrescription where safe dispensation may require reliable identification of substances in available products. 19 countries are represented, including 26 national Drug and eHealth Agencies. Stakeholders are involved through their associations. Duration is 4 years, budget € 21 m, with requested funding € 19 m.